Glyx Therapeutics and SATT Nord Make Their Exclusive License Official, and Glyx Features in the Regional Media
October 2026 — Amiens, France Glyx Therapeutics has an exclusive license agreement with SATT Nord (Société d’Accélération du Transfert de Technologies Nord), signed on April 21, 2026, covering the European patent family EP21306658 / WO2023094699 and the associated know-how. On October 13, 2026, the agreement was officially celebrated with the directors of the universities concerned, […]
